{
  "ticker": "IRX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971459",
  "id": "02971459",
  "pages": 5,
  "price_sensitive": true,
  "date": "20250722",
  "time": "1137",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250722/pdf/06m0tbxv7tl0rv.pdf",
  "summary": "### **INHALERX LIMITED \u2013 Appendix 4C Summary (Q2 2025)**  \n\n#### **Key Financial Highlights**  \n- **Cash Flow from Operating Activities**:  \n  - Net cash inflow of **$170K** (Q2), **$39K** (YTD).  \n  - **Government grants/tax incentives**: **$489K** (Q2 & YTD).  \n  - **Operating expenses**: R&D ($196K), admin ($119K), staff ($10K).  \n\n- **Cash Position**:  \n  - **Closing cash**: **$480K** (vs. $63K last quarter).  \n  - **Total available funding**: **$38.8M** (cash + undrawn facility).  \n\n- **Financing**:  \n  - **$247K** drawn during Q2 from **$38.5M facility** (Clendon Biotech Capital).  \n  - Facility terms: **15% interest**, secured for clinical trial costs (Phase 2 completion).  \n\n- **Related-Party Payments**:  \n  - **$28K** total (salaries, director fees).  \n\n#### **Material Takeaways**  \n1. **Positive operating cash flow** bolstered by grants, but core operations remain cash-intensive (R&D focus).  \n2. **Significant undrawn facility** ($38.3M) ensures near-term liquidity for clinical trials.  \n3. **High-interest debt** (15%) may pressure future profitability if trials are delayed.  \n\n**No material capital-raising or operational shocks identified.**  \n\n*(Note: \"N/A\" fields denote positive operating cash flow, eliminating near-term funding concerns.)*",
  "usage": {
    "prompt_tokens": 2945,
    "completion_tokens": 346,
    "total_tokens": 3291,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T03:22:55.241451"
}